J. Donahue to Treatment Outcome
This is a "connection" page, showing publications J. Donahue has written about Treatment Outcome.
Connection Strength
0.258
-
Wolfram JA, Donahue JK. Gene therapy to treat cardiovascular disease. J Am Heart Assoc. 2013 Aug 20; 2(4):e000119.
Score: 0.051
-
Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, Donahue JK. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012 Jan 17; 125(2):216-25.
Score: 0.045
-
Donahue JK. Advice for management of the long-QT patient. J Cardiovasc Electrophysiol. 2010 Aug 01; 21(8):902-4.
Score: 0.040
-
Donahue JK, Sasano T, Kelemen K. Gene therapy approaches to ventricular tachyarrhythmias. J Electrocardiol. 2007 Nov-Dec; 40(6 Suppl):S187-91.
Score: 0.034
-
Tandri H, Griffith LS, Tang T, Nasir K, Zardkoohi O, Reddy CV, Capps M, Calkins H, Donahue JK. Clinical course and long-term follow-up of patients receiving implantable cardioverter-defibrillators. Heart Rhythm. 2006 Jul; 3(7):762-8.
Score: 0.031
-
Sardana M, Ogunsua AA, Spring M, Shaikh A, Asamoah O, Stokken G, Browning C, Ennis C, Donahue JK, Rosenthal LS, Floyd KC, Aurigemma GP, Parikh NI, McManus DD. Association of Left Atrial Function Index With Late Atrial Fibrillation Recurrence after Catheter Ablation. J Cardiovasc Electrophysiol. 2016 12; 27(12):1411-1419.
Score: 0.016
-
Shaikh AY, Esa N, Martin-Doyle W, Kinno M, Nieto I, Floyd KC, Browning C, Ennis C, Donahue JK, Rosenthal LS, McManus DD. Addition of B-Type Natriuretic Peptide to Existing Clinical Risk Scores Enhances Identification of Patients at Risk for Atrial Fibrillation Recurrence After Pulmonary Vein Isolation. Crit Pathw Cardiol. 2015 Dec; 14(4):157-65.
Score: 0.015
-
Panda NC, Zuckerman ST, Mesubi OO, Rosenbaum DS, Penn MS, Donahue JK, Alsberg E, Laurita KR. Improved conduction and increased cell retention in healed MI using mesenchymal stem cells suspended in alginate hydrogel. J Interv Card Electrophysiol. 2014 Nov; 41(2):117-27.
Score: 0.014
-
Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz G, Donahue JK, Rivers R, Balkissoon J, Handa JT, Campochiaro PA, Nguyen QD. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013 Jan 14; 14:7.
Score: 0.012